GRAIL, Inc. (GRAL)
139.56
+5.80
(+4.34%)
USD |
NASDAQ |
Nov 03, 16:00
141.09
+1.53
(+1.10%)
After-Hours: 17:14
GRAIL Enterprise Value : 5.204B for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 5.204B |
| October 30, 2026 | 5.636B |
| October 29, 2026 | 6.328B |
| October 28, 2026 | 6.282B |
| October 27, 2026 | 5.957B |
| October 26, 2026 | 5.479B |
| October 23, 2026 | 5.150B |
| October 22, 2026 | 4.905B |
| October 21, 2026 | 5.152B |
| October 20, 2026 | 4.798B |
| October 19, 2026 | 4.698B |
| October 16, 2026 | 4.492B |
| October 15, 2026 | 5.280B |
| October 14, 2026 | 5.470B |
| October 13, 2026 | 5.499B |
| October 12, 2026 | 5.365B |
| October 09, 2026 | 5.509B |
| October 08, 2026 | 5.153B |
| October 07, 2026 | 5.166B |
| October 06, 2026 | 5.361B |
| October 05, 2026 | 6.112B |
| October 02, 2026 | 5.629B |
| October 01, 2026 | 5.151B |
| September 30, 2026 | 5.488B |
| September 29, 2026 | 5.330B |
| Date | Value |
|---|---|
| September 28, 2026 | 5.154B |
| September 25, 2026 | 4.897B |
| September 24, 2026 | 4.822B |
| September 23, 2026 | 4.077B |
| September 22, 2026 | 4.077B |
| September 21, 2026 | 4.052B |
| September 18, 2026 | 2.837B |
| September 17, 2026 | 2.801B |
| September 16, 2026 | 2.585B |
| September 15, 2026 | 2.619B |
| September 14, 2026 | 2.603B |
| September 11, 2026 | 2.635B |
| September 10, 2026 | 2.694B |
| September 09, 2026 | 2.690B |
| September 08, 2026 | 2.763B |
| September 04, 2026 | 2.818B |
| September 03, 2026 | 2.831B |
| September 02, 2026 | 2.828B |
| September 01, 2026 | 2.794B |
| August 31, 2026 | 2.775B |
| August 28, 2026 | 2.803B |
| August 27, 2026 | 2.915B |
| August 26, 2026 | 2.785B |
| August 25, 2026 | 2.916B |
| August 24, 2026 | 2.650B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 84.26B |
| Twist Bioscience Corp. | 8.014B |
| Prime Medicine, Inc. | 819.88M |
| Kailera Therapeutics, Inc. | 668.36M |
| Arrowhead Pharmaceuticals, Inc. | 8.182B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| EPS Diluted (Quarterly) | -2.557 |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -6.99% |
| Normalized Earnings Yield | -6.689 |